News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

AbSorber AB Has Received Patent Protection For The Transplantation Crossmatch Test XM-ONE® In New Zealand



10/21/2008 2:41:57 PM

AbSorber has received patent protection for the transplantation crossmatch test XM-ONE® in New Zealand. New Zealand is thereby the first country to approve a patent for AbSorber’s product.

Getting the patent approved is not only important for AbSorber’s intellectually property strategy for the product but it also demonstrates that the authorities in New Zealand see the product as unique. AbSorber has a patent applications pending for XM-ONE® in the US, EU region, Japan and other key transplantation markets, and expect more regions to follow New Zealand and approve the XM-ONE® patent.AbSorber has received patent protection for the transplantation crossmatch test XM-ONE® in New Zealand. New Zealand is thereby the first country to approve a patent for AbSorber’s product.

AbSorber’s transplantation crossmatch test XM-ONE® is unique in that it is the first standardized test that can detect antibodies against the cells that line the inside of blood vessels. These endothelial cells are the first point of contact between the transplanted organ and the recipient’s immune system. Anti-endothelial cell antibodies have been shown to play a key role in causing post-transplantation rejections.

The patent approved in New Zealand comprises the preparation of the cells used in the test as well as how they are used in the crossmatch test. AbSorber’s largest owner is LinkMed, a listed private equity company investing in life science companies.

For more information contact: Anders Karlsson, CEO AbSorber, tel. + 46 70 918 00 10 Also visit www.absorber.se and www.linkmed.se AbSorber develops products that facilitate more successful transplantations.

AbSorber’s first product, the transplantation test XM-ONE® detects key antibodies responsible for post-transplantation rejection reactions. XM-ONE® is already CE marked and FDA approved for sales in the EU and U.S. LinkMed, in collaboration with innovators, develops new life science companies.

By contributing entrepreneurship and capital, LinkMed has created a portfolio of eleven companies, six in drug development and biotechnology and five in medical technology. The company’s principal owners are FastPartner, Koncentra Holding, and the founder Ingemar Lagerlöf. The LinkMed share is listed on the OMX Nordic Exchange Stockholm in the small-cap sector (ticker:LMED). See www.linkmed.se for more information.


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES